Greater specificity

Control herds efficiently and cull infected cattle with confidence. The IDEXX ELISA Test detects antibodies against bovine leukemia virus (BLV) in individual or pools of up to 10 individual serum or plasma samples.

More countries are recognizing the need for eradication of enzootic bovine leukemia in herds. With no available vaccine or treatment, testing and separating or culling infected cattle is the only effective control. For enzootic bovine leukemia, OIE prescribes the ELISA as a test to be used for international trade.¹

Countries free from enzootic bovine leukemia qualify and maintain their status by retesting their cattle population at intervals of no more than 36 months.¹

The IDEXX Leukosis Serum X2 Ab Test offers:

- BLV antibody detection by antigens produced on new cell line
- Very high specificity—reduces the need for verification
- Excellent sensitivity—fulfills OIE prescriptions and EU directives²
- Detection of antibodies against viral proteins including the highly immunogenic early-appearing glycoprotein gp51
- Modern kit format—easy to use, with ready-to-use reagents
- High sample throughput—automation saves time and cost
- Easy data management—can be used with xChek* software
The IDEXX ELISA test shows excellent specificity.

High diagnostic specificity of 99.4%–100% (2,000 negative samples from different regions of Europe)^3

Negative serum samples (n=864) from Swiss cattle (99.9% specificity).

Distribution of pooled sera (pools of ten individual samples) from different regions of Europe (100% specificity). Very high correlation between the short and long sample incubation protocol.

Excellent sensitivity: The international reference sample E4 scores positive at a dilution of 1/10 (single samples) and 1/100 (pool of ten individual samples).

For more information about the IDEXX Leukosis Serum X2 Ab Test, please contact your IDEXX representative or visit idexx.com/blv.